CGEN Compugen (CGEN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001119774
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
29
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $1.6K priced
What the filings say about CGEN
Insiders, 180 days
-$4.7K net sold
1 seller · 0% of sales under a 10b5-1 plan
Compugen insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, COMPUGEN LTD insiders sold a net $4.7K of stock across 11 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Apr 24, 2026.
- The trade is 6.4% of the 29,375 shares held after it.
- No other insider sold within 30 days.
- 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Business Development Levine Zurit sold about $4.7K of CGEN on Jul 9, 2026; 29 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Apr 14, 2026.
- The trade is 6.8% of the 29,375 shares held after it.
- 1 other insider sold within 30 days.
- 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Business Development Levine Zurit sold about $6.4K of CGEN on Apr 24, 2026; 1 other insider sold within 30 days and 29 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 14, 2026.
- The trade is 44.0% of the 11,375 shares held after it.
- 1 other insider sold within 30 days.
- 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Ophir Eran sold about $16.0K of CGEN on Apr 24, 2026; 1 other insider sold within 30 days and 29 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Apr 1, 2026.
- The trade is 44.0% of the 11,375 shares held after it.
- 1 other insider sold within 30 days.
- 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Ophir Eran sold about $14.5K of CGEN on Apr 14, 2026; 1 other insider sold within 30 days and 29 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Apr 10, 2026.
- The trade is 6.8% of the 29,375 shares held after it.
- 1 other insider sold within 30 days.
- 29 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Business Development Levine Zurit sold about $5.6K of CGEN on Apr 14, 2026; 1 other insider sold within 30 days and 29 funds added in the latest 13F quarter.11 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$4.7K over 180 days
more than 62% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
29 funds bought in last quarter
below 62% of Pharma & Biotech
Revenue
+161.1% year over year
more than 88% of Pharma & Biotech
Margin
48.6% net margin
more than 95% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
2.5% of the float short (float per yahoo 2026-10-26) · 16.1 days to cover · settled 2026-09-30
below 63% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CGEN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+12.6%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CGEN: institutional holders (13F)
13F holdings, latest reported quarter
3,184,257 sh
$6.8M
1,877,500 sh
$4.0M
1,051,986 sh
$2.3M
1,020,000 sh
$2.2M
842,181 sh
$1.8M
Congress trades in CGEN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CGEN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CGEN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Taylor Frigon Core Growth Fund
$639.0K position · as of 2026-05-31
1.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
5 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
1 active
2
Multi-phase
1 active
What changed recently
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sens
2026-10-07 · Recruiting → Active Not Recruiting
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $4.7K sold by insiders over 180 days, 29 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CGEN financials
Revenue growth
+161.1%
XBRL, annual
Net margin
48.6%
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $72.8M | $27.9M | $33.5M | $7.5M |
| Gross profit | $63.5M | $19.9M | $31.5M | $6.5M |
| Operating income | $31.3M | -$14.9M | -$13.0M | -$35.4M |
| Net income | $35.3M | -$14.2M | -$18.8M | -$33.7M |
| EPS (diluted) | 0.38 | -0.16 | -0.21 | -0.39 |
| Operating cash flow | $31.6M | $49.6M | -$35.9M | -$34.1M |
| Cash | $90.6M | $18.2M | $13.9M | $11.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
CGEN Stock Sonar score 4/7 axes
Find similar shapesCompareCGEN ranks highest on growth (85th percentile) and risk and compliance (70th), and lowest on insider conviction (30th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CGEN filings, in plain words
Are Compugen insiders buying or selling CGEN?
In the 180 days to 2026-10-28, Compugen insiders were net sellers, a net $4.7K across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Compugen insiders were net sellers of CGEN, a net $4.7K across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
